PIK3CA and neoplasm: Combining PI3K pathway inhibitors with immune checkpoint blockade is mechanistically attractive: PI3K modulation can remodel tumor-associated myeloid cells, reduce immunosuppressive cell populations, and augment T-cell effector function, thereby potentiating responses to PD-1-1/PD-PD-L1 blockade in some preclinical models.